

Further Delay in Lodgement of Appendix 4D and Half-Year Report for the Half-Year Ended 31st December 2023

Sydney, Australia – 25 March 2024: Cannabis focused drug development and product innovation company Bod Science Limited (Administrators Appointed) (“Bod” or “Company”) (ASX: BOD) advised the ASX on 29th February 2024 that it expected that its Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 would be lodged by 28th March 2024, dependent upon receiving ASIC’s consent to a change in auditor within the expected timeframe.

The Company was advised by ASIC on 22nd March 2024 that it had rejected the application of Bod’s incumbent auditor, Nexia Sydney Audit Pty Ltd, to resign as the Company’s auditor due to a perceived conflict of interest.

Due to delays in receiving the ASIC decision, the Company’s half-year review by Nexia Sydney Audit Pty Ltd has not yet commenced and the Company will not meet the previously advised expected lodgement date of 28th March 2024.

The Company now expects that the Appendix 4D and Half-Year Report for the half-year ended 31st December 2023 will be lodged with the ASX by 30th April 2024.

This announcement has been approved by the administrator of Bod Science Limited (under administration).

-ENDS-

About Bod Science:

Bod Science Limited (Administrators Appointed) (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018